30th Mar 2016 06:53
LONDON (Alliance News) - Respiratory drug development firm Skyepharma PLC on Wednesday said partner Mundipharma has received confirmation the marketing authorisation for a breath-acuated version of the Flutiform asthma treatment has been accepted for review in Europe.
The breath-actuated version of Flutiform uses Mundipharma's K-Haler device. If the product is approved and launched, Skyepharma would be eligible for revenue from the product from royalties and milestone payments.
"Flutiform K-Haler has been designed to build on the success of Flutiform in the treatment of asthma, and its development has demonstrated Mundipharma's strong commitment to expanding the Flutiform franchise. Skyepharma has worked closely with Mundipharma in this development which we believe is an important potential extension of the Flutiform range," said Skyepharma Chief Executive Peter Grant.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
SKP.L